Human Leukocyte Antigen (HLA) Influence on Prognosis of Autoimmune Hearing Loss.
HLA antigens
HLA-DRB1* alleles
autoantibodies
autoimmunity
hearing loss
Journal
Audiology research
ISSN: 2039-4330
Titre abrégé: Audiol Res
Pays: Switzerland
ID NLM: 101644681
Informations de publication
Date de publication:
25 Jan 2021
25 Jan 2021
Historique:
received:
24
11
2020
revised:
31
12
2020
accepted:
21
01
2021
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
29
1
2021
Statut:
epublish
Résumé
To evaluate the effect of human leukocyte antigen (HLA) on hearing outcome in patients suffering from autoimmune hearing loss (AIHL). The diagnosis of AIHL was essentially based on clinical symptoms, such as recurrent, sudden, fluctuating, or quickly progressing (<12 months) sensorineural hearing loss (uni-/bilateral). The molecular typing of HLA alleles was achieved by using polymerase chain reaction procedures. Patients underwent a tapering schema of steroid treatment and audiometric features were recorded. A logistic regression model was used to identify which HLA typing alleles were statistically significant in patients' response to treatment. Forty patients with AIHL were found to be carriers of HLA B27, B35, B51, C4, C7, and DRB1*04 alleles. No statistically significant influence of HLA B27, B35, B51, C4, C7, DRB1*04 HLA alleles typing was detected for the prognosis of AIHL. In these patients, the onset of AIHL was mainly progressive (53.8%), 29.2% of them had moderate hearing loss, and most of the cases had both bilateral hearing loss (62.5%) and downsloping audiogram (40%). The presence of HLA B27, B35, B51, C4, C7, and DRB1*04 alleles had no significant effect on a favorable outcome of AIHL. However, larger samples of patients are necessary in order to improve the knowledge about the HLA influence on the clinical course of AIHL.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the effect of human leukocyte antigen (HLA) on hearing outcome in patients suffering from autoimmune hearing loss (AIHL).
MATERIALS AND METHODS
METHODS
The diagnosis of AIHL was essentially based on clinical symptoms, such as recurrent, sudden, fluctuating, or quickly progressing (<12 months) sensorineural hearing loss (uni-/bilateral). The molecular typing of HLA alleles was achieved by using polymerase chain reaction procedures. Patients underwent a tapering schema of steroid treatment and audiometric features were recorded. A logistic regression model was used to identify which HLA typing alleles were statistically significant in patients' response to treatment.
RESULTS
RESULTS
Forty patients with AIHL were found to be carriers of HLA B27, B35, B51, C4, C7, and DRB1*04 alleles. No statistically significant influence of HLA B27, B35, B51, C4, C7, DRB1*04 HLA alleles typing was detected for the prognosis of AIHL. In these patients, the onset of AIHL was mainly progressive (53.8%), 29.2% of them had moderate hearing loss, and most of the cases had both bilateral hearing loss (62.5%) and downsloping audiogram (40%).
CONCLUSION
CONCLUSIONS
The presence of HLA B27, B35, B51, C4, C7, and DRB1*04 alleles had no significant effect on a favorable outcome of AIHL. However, larger samples of patients are necessary in order to improve the knowledge about the HLA influence on the clinical course of AIHL.
Identifiants
pubmed: 33503870
pii: audiolres11010004
doi: 10.3390/audiolres11010004
pmc: PMC7838950
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31-37Références
Ear Nose Throat J. 2010 Mar;89(3):122-7
pubmed: 20229477
Curr Opin Otolaryngol Head Neck Surg. 2004 Oct;12(5):426-30
pubmed: 15377956
Hum Immunol. 2000 Jun;61(6):615-23
pubmed: 10825590
Acta Otorrinolaringol Esp. 2018 Jul - Aug;69(4):214-218
pubmed: 29033124
Acta Otolaryngol Suppl. 2002;(548):26-9
pubmed: 12211352
J Laryngol Otol. 2003 Oct;117(10):775-9
pubmed: 14653918
Semin Arthritis Rheum. 2004 Oct;34(2):544-8
pubmed: 15505770
Ann Otol Rhinol Laryngol. 1996 Aug;105(8):628-33
pubmed: 8712634
Sci Rep. 2014 Nov 10;4:6887
pubmed: 25382027
Clin Case Rep. 2014 Dec;2(6):310-2
pubmed: 25548635
Laryngoscope. 1987 Jan;97(1):7-9
pubmed: 3491944
Laryngoscope. 2003 Oct;113(10):1770-6
pubmed: 14520104
J Immunol Res. 2018 Aug 19;2018:5798103
pubmed: 30211232
Acta Otolaryngol. 2005 Aug;125(8):814-8
pubmed: 16158526
J Immunol. 2006 Sep 15;177(6):4203-10
pubmed: 16951386
Laryngoscope. 1990 May;100(5):516-24
pubmed: 2329911
Int J Audiol. 2020 Apr;59(4):243-253
pubmed: 31714154
Semin Arthritis Rheum. 2004 Oct;34(2):538-43
pubmed: 15505769
Acta Otolaryngol. 2000 Sep;120(6):710-5
pubmed: 11099146
Acta Otolaryngol. 2005 Dec;125(12):1277-82
pubmed: 16303674
Acta Otolaryngol. 2006 Oct;126(10):1012-21
pubmed: 16923703
Acta Otolaryngol. 2017 Aug;137(8):823-828
pubmed: 28296514
Int J Immunogenet. 2010 Dec;37(6):509-11
pubmed: 20572893
Rheumatology (Oxford). 2013 May;52(5):780-9
pubmed: 23436581
Int Arch Otorhinolaryngol. 2017 Jul;21(3):213-223
pubmed: 28680488
Eur Arch Otorhinolaryngol. 2019 Dec;276(12):3267-3274
pubmed: 31605190
Eur Arch Otorhinolaryngol. 2002 Aug;259(7):347-50
pubmed: 12189399
Int J Immunopathol Pharmacol. 2018 Mar-Dec;32:2058738418808680
pubmed: 30376736
Endocrine. 2015 Dec;50(3):708-14
pubmed: 25963023
Arch Otolaryngol Head Neck Surg. 2005 Aug;131(8):665-72
pubmed: 16103296
Hear Res. 2005 May;203(1-2):28-31
pubmed: 15855027
Otol Neurotol. 2010 Jun;31(4):687-90
pubmed: 20400925
Ann Otol Rhinol Laryngol. 1979 Sep-Oct;88(5 Pt 1):585-9
pubmed: 496191
PLoS One. 2013 May 30;8(5):e64108
pubmed: 23737967